[Recent advances in histiocytosis]

Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.

[Recent advances in histiocytosis]

Pediatr Med Chir. 1985 Mar-Apr;7(2):181-8. Unique Identifier : AIDSLINE MED/86148695
Nespoli L; Arico M; Burgio VL

Abstract: Histiocytosis is the term currently used to describe the group of diseases characterized by activation and proliferation of monocytic-mononuclear cells. Some of these are reactive to well-known causes, mycobacteriae, viral and parasitic infections, or chronic storage of minerals. Wider and more intriguing is the group of histiocytosis secondary to unknown causes: sinus histiocytosis with massive lymphadenopathy; histiocytosis in the course of systemic illnesses such as rheumatoid arthritis, SLE, Crohn disease, ulcerative colity, sarcoidosis, Weber-Christian disease, Wegener granulomatosis. Histiocitytosis X is the most frequent type of histiocytosis. Hematophagocytosis is a paraphysiologic phenomenon; however, when enormously increased it is characteristic of both the virus-associated hemophagocytic syndrome and Farquhar syndrome. In some cases of severe combined immunodeficiencies (SCID) histiocytic proliferation has been observed. Finally, during the past decade the morphologic approach has led to definition of the X-linked lymphoproliferative disease (XLP) and its erroneous classification as histiocytosis. These conditions are reviewed and some clinical cases are reported.

Keywords: Cell Differentiation Child Child, Preschool Diagnosis, Differential English Abstract Female Histiocytes/PHYSIOPATHOLOGY Histiocytosis, Langerhans-Cell/DIAGNOSIS/THERAPY Human Immunologic Deficiency Syndromes/COMPLICATIONS Infant Infant, Newborn Linkage (Genetics) Lymphoproliferative Disorders/GENETICS Male Pedigree Phagocytosis Reticuloendotheliosis/*CLASSIFICATION/DRUG THERAPY/ETIOLOGY X Chromosome JOURNAL ARTICLE

860630
M8660222

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1986. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1986. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .